The content on this site is intended for healthcare professionals only
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC
20 year followup on high-dose chemo with HSCT in high-risk breast cancer
Opportunities for biosimilars in practice and education
Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer
VALENTINO: Maintenance therapy in advanced CRC
Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA
The Circulating Cell-Free Genome Atlas Study
The standard of care and progress so far with PARP inhibitors for ovarian cancer
Cardiac events in stage III NSCLC treated in daily clinical practice
Ceritinib and ribociclib in ALK-positive NSCLC
Cemiplimab in patients with hepatocellular carcinoma
